Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 2Withdrawn 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Multiple Myeloma 9Recurrence 2Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms, Plasma Cell 1Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic 1Leukemia, Plasma Cell 1Immunoglobulin Light-chain Amyloidosis 1Hematologic Neoplasms 1Amyloidosis 1

Interventions

Cyclophosphamide 13Peripheral Blood Stem Cell Transplantation 9Methotrexate 9Cytarabine 9fludarabine phosphate 8fludarabine 8Radiotherapy 7Vincristine 5Cyclosporine 5Whole-Body Irradiation 4Prednisone 4Mycophenolic Acid 4Melphalan 4Filgrastim 4Etoposide 4Busulfan 4asparaginase erwinia chrysanthemi recombinant 3Tacrolimus 3Sirolimus 3Dasatinib 3Cord Blood Stem Cell Transplantation 3Bortezomib 3Asparaginase 3prednylidene 2pegaspargase 2ixazomib 2deltacortene 2blinatumomab 2Thiotepa 2Therapeutics 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Precursor Cell Lymphoblastic Leukemia-Lymphoma × daratumumab × Clear all
NCT06570915 2026-05-13

T-ALL-2024

Institute of Hematology & Blood Diseases Hospital, China

Phase 2 Withdrawn
LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡